Find disease awareness content and relevant supporting materials
Impact of weight loss and eating difficulties on health-related quality of life up to 10 years after oesophagectomy for cancer.
Severe weight loss is experienced by patients with eating difficulties after surgery for oesophageal cancer. The aim of this prospective cohort study was to assess the influence of eating difficulties and severe weight loss...
NICE recommends the use of Opdivo in resected oesophageal or gastro-oesophageal junction cancer.
The UK's National Institute for Health and Care Excellence (NICE) has recommended Opdivo (nivolumab), from Bristol Myers Squibb, as a treatment for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients.
Quality of life in a randomized trial of early closure of temporary ileostomy after rectal resection for cancer (EASY trial).
Background: A temporary ileostomy may reduce symptoms from anastomotic leakage after rectal cancer resection. Earlier results of the EASY trial showed that early closure of the temporary ileostomy was associated with significantly fewer postoperative complications.
Phase III CheckMate-577 trial of Opdivo shows benefits in oesophageal cancer.- BMS
Bristol Myers Squibb announced that checkpoint inhibitor treatment Opdivo (nivolumab) demonstrated its efficacy in the phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction cancers who had previously received neoadjuvant chemoradiation therapy and tumour resection.
Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa�) versus placebo in oesophageal cancer progressing after chemotherapy.
To assess whether gefitinib will improve overall survival in patients with oesophageal cancer when compared to a placebo.